There's a lot of growth on the way, and soon. CRISPR Therapeutics' (CRSP -0.56%) stock may be down by 21% this year so far, but that doesn't mean you should write it off as a potential investment. The innovative developer of gene therapies is making headway. And its pipeline implies a cornucopia of opportunities for the stock to rise over the coming years, especially if its cardiovascular medicine and oncology programs pan out. Still, investing in biotech companies isn't for the faint of heart, and even a s ...

I am a former Senior Manager at a Big Four accounting firm and have been a CPA for over 20 years. After leaving public accounting in 2010, I have been the CFO of two privately held companies with sales between $50m and $100m in both the aerospace and defense and beauty industries. At my core, I like to think of myself as a value investor, though I will step into other disciplines if I think it makes sense. I have been investing since 1999, so I have seen a few different market cycles and have tried my hand ...

It's an excellent opportunity to buy shares of what could become a biotech giant on the dip. In the past three years, CRISPR Therapeutics (CRSP -0.33%) has made tremendous progress. It was still a clinical-stage biotech in 2021, but it now has a gene-editing therapy that is approved in multiple countries. However, this regulatory milestone hasn't been accompanied by a strong stock market performance. CRISPR Therapeutics has significantly lagged the market since 2021. What is going on with this gene-editing ...

An investment in these players today could score a big win down the road. Why do investors love biotech stocks? Because these players often work on game-changing technology that could lead to tomorrow's game-changing treatment -- and potentially blockbuster revenue. As an investor, you often have to be patient, as it takes years for a company to bring a candidate through development and reach the billion-dollar revenue stage. And you have to be comfortable with a bit of risk too, because candidate failure a ...

Core Viewpoint - CRISPR Therapeutics has experienced a significant decline in stock price despite the potential of its gene-editing therapy, Casgevy, which could generate substantial revenue in the future [1][2][3] Group 1: Financial Performance - Year-to-date, CRISPR's shares are down 24%, far from its 52-week high of over $91 [1] - The company incurred a net loss of $243 million in the first half of the year, indicating ongoing financial challenges [4] - CRISPR has $2 billion in cash and cash equivalents, providing a solid financial foundation to sustain operations without immediate cash raises [4] Group 2: Product Pipeline and Market Potential - Casgevy, a treatment for sickle cell disease and beta thalassemia, is expected to generate billions in revenue, but analysts predict it won't exceed $1 billion until 2027 [2][3] - CRISPR is also developing other treatments, including CTX211 for type 1 diabetes and multiple cancer therapies, with preliminary data expected later this year [5][6] - The gene therapy market is currently valued at around $6 billion but is projected to grow to over $18 billion by the end of the decade [6] Group 3: Investment Outlook - CRISPR is viewed as a long-term investment opportunity, with a market capitalization of just over $4 billion, suggesting significant upside potential if additional treatments gain approval [7] - The company is not a typical high-risk biotech startup, as it has an approved treatment and ample liquid resources to support its operations [8] - Despite current market focus on artificial intelligence and tech stocks, CRISPR may present a compelling buy for patient investors, with the potential for substantial long-term returns [9]

A month has gone by since the last earnings report for CRISPR Therapeutics AG (CRSP) . Shares have lost about 7.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is CRISPR Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Q2 Loss Wider-Than-Expected, S ...

These companies are nearly in the sweet spot of risk versus reward in biotech. Many investors rightfully identify biotech stocks as being riskier than average, and those stocks certainly have a habit of earning their reputation. Still, there are a few up-and-coming biotechs that have revenue and a clear path to generating even more in the near term, which makes them notably steadier than their earlier-stage peers that don't yet have the certainty of selling anything at all. With that in mind, let's examine ...

The companies are chasing major innovations. Exciting trends are sweeping through the biotech industry. One of them is the race to develop breakthrough weight loss medicines, an area that is projected to grow by leaps and bounds through the end of the decade. Gene editing, a set of techniques that are allowing researchers to unlock therapies for diseases that have been untouchable, is another one. Companies, particularly relatively small ones that make breakthroughs in these fields, could deliver marketcrus ...

Core Viewpoint - CRISPR Therapeutics (CRSP) has underperformed in the market despite receiving regulatory approval for its gene therapy Casgevy, which is the first CRISPR-based gene-editing therapy approved globally [1][3][11] Company Developments - CRSP's stock has declined 23.6% year-to-date, while the industry has only fallen by 1.7% [1][3] - The company received approval for Casgevy, a one-shot gene therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), in the U.S. and Europe [3][4] - Casgevy is expected to provide a new treatment option for approximately 35,000 patients in the U.S. and Europe, with revenue generation anticipated to start in the second half of 2024 [4][5] Partnership Insights - CRISPR has a solid partnership with Vertex Pharmaceuticals, which began in 2015, focusing on gene editing therapies for various conditions [6][7] - The collaboration has expanded to include therapies for cystic fibrosis, Duchenne Muscular Dystrophy (DMD), and Myotonic Dystrophy Type 1 (DM1) [6] - CRISPR is eligible for over $1.3 billion in milestone payments and royalties from therapies developed under this partnership [7] Financial Metrics - CRISPR's shares are trading at a price-to-book (P/B) ratio of 2.05, which is lower than the industry average of 4.58 [8] - Loss estimates for 2024 have slightly improved from $5.65 to $5.61, while 2025 estimates have widened from $4.44 to $4.92 due to increased R&D costs [8][9] Market Position - The approval of Casgevy gives CRISPR an advantage over competitors like Beam Therapeutics and Editas Medicine, which are still in earlier stages of developing their therapies for SCD and TDT [11] - Management is also focusing on in vivo candidates, with two new candidates currently in phase I clinical studies [12]

Bevan Goldswain/E+ via Getty Images Introduction Shares of CRISPR Therapeutics (NASDAQ:CRSP) have been on a rollercoaster ride as of late. I've been following the company closely for over a year now. Remember that CRISPR secured FDA approval last December for its gene therapy targeting sickle cell disease, Casgevy. On the same day, bluebird bio (BLUE), too, received the green light for its sickle cell gene therapy, Lyfgenia. My attitude toward CRISPR has always been cautious, even after Casgevy's groundbrea ...